These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 23839909)

  • 1. Elevated serum BAFF levels are associated with rising anti-double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus.
    Carter LM; Isenberg DA; Ehrenstein MR
    Arthritis Rheum; 2013 Oct; 65(10):2672-9. PubMed ID: 23839909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response.
    Cambridge G; Isenberg DA; Edwards JC; Leandro MJ; Migone TS; Teodorescu M; Stohl W
    Ann Rheum Dis; 2008 Jul; 67(7):1011-6. PubMed ID: 17962238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients.
    Lu TY; Ng KP; Cambridge G; Leandro MJ; Edwards JC; Ehrenstein M; Isenberg DA
    Arthritis Rheum; 2009 Apr; 61(4):482-7. PubMed ID: 19333973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of B-cell depletion therapy on serological evidence of B-cell and plasmablast activation in patients with rheumatoid arthritis over multiple cycles of rituximab treatment.
    Cambridge G; Perry HC; Nogueira L; Serre G; Parsons HM; De La Torre I; Dickson MC; Leandro MJ; Edwards JC
    J Autoimmun; 2014 May; 50():67-76. PubMed ID: 24365380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response.
    Ng KP; Cambridge G; Leandro MJ; Edwards JC; Ehrenstein M; Isenberg DA
    Ann Rheum Dis; 2007 Sep; 66(9):1259-62. PubMed ID: 17412738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients: a steroid-sparing regimen.
    Ezeonyeji AN; Isenberg DA
    Rheumatology (Oxford); 2012 Mar; 51(3):476-81. PubMed ID: 22096015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis.
    Vallerskog T; Heimbürger M; Gunnarsson I; Zhou W; Wahren-Herlenius M; Trollmo C; Malmström V
    Arthritis Res Ther; 2006; 8(6):R167. PubMed ID: 17092341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse.
    Cambridge G; Stohl W; Leandro MJ; Migone TS; Hilbert DM; Edwards JC
    Arthritis Rheum; 2006 Mar; 54(3):723-32. PubMed ID: 16508933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles.
    Cambridge G; Leandro MJ; Teodorescu M; Manson J; Rahman A; Isenberg DA; Edwards JC
    Arthritis Rheum; 2006 Nov; 54(11):3612-22. PubMed ID: 17075806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. B-cell-activating factor receptor expression on naive and memory B cells: relationship with relapse in patients with rheumatoid arthritis following B-cell depletion therapy.
    de la Torre I; Moura RA; Leandro MJ; Edwards J; Cambridge G
    Ann Rheum Dis; 2010 Dec; 69(12):2181-8. PubMed ID: 20581016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of B-cell activating factor of the tumour necrosis factor family (BAFF) in T cells in active systemic lupus erythematosus: the role of BAFF in T cell-dependent B cell pathogenic autoantibody production.
    Morimoto S; Nakano S; Watanabe T; Tamayama Y; Mitsuo A; Nakiri Y; Suzuki J; Nozawa K; Amano H; Tokano Y; Kobata T; Takasaki Y
    Rheumatology (Oxford); 2007 Jul; 46(7):1083-6. PubMed ID: 17500077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum BAFF concentrations in patients with Graves' disease and orbitopathy before and after immunosuppressive therapy.
    Vannucchi G; Covelli D; Currò N; Dazzi D; Maffini A; Campi I; Bonara P; Guastella C; Pignataro L; Ratiglia R; Beck-Peccoz P; Salvi M
    J Clin Endocrinol Metab; 2012 May; 97(5):E755-9. PubMed ID: 22399512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of serum B cell activating factor from the tumour necrosis factor family (BAFF) and a proliferation-inducing ligand (APRIL) with central nervous system and renal disease in systemic lupus erythematosus.
    Vincent FB; Northcott M; Hoi A; Mackay F; Morand EF
    Lupus; 2013 Aug; 22(9):873-84. PubMed ID: 23846230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum levels of tumour necrosis factor family members a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BLyS) are inversely correlated in systemic lupus erythematosus.
    Morel J; Roubille C; Planelles L; Rocha C; Fernandez L; Lukas C; Hahne M; Combe B
    Ann Rheum Dis; 2009 Jun; 68(6):997-1002. PubMed ID: 18676986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy of repeated treatment with B-cell depletion therapy in systemic lupus erythematosus: an evaluation.
    Turner-Stokes T; Lu TY; Ehrenstein MR; Giles I; Rahman A; Isenberg DA
    Rheumatology (Oxford); 2011 Aug; 50(8):1401-8. PubMed ID: 21398661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome.
    Pers JO; Devauchelle V; Daridon C; Bendaoud B; Le Berre R; Bordron A; Hutin P; Renaudineau Y; Dueymes M; Loisel S; Berthou C; Saraux A; Youinou P
    Arthritis Rheum; 2007 May; 56(5):1464-77. PubMed ID: 17469105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Takayasu arteritis is characterised by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab.
    Hoyer BF; Mumtaz IM; Loddenkemper K; Bruns A; Sengler C; Hermann KG; Maza S; Keitzer R; Burmester GR; Buttgereit F; Radbruch A; Hiepe F
    Ann Rheum Dis; 2012 Jan; 71(1):75-9. PubMed ID: 21953334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune complexes containing serum B-cell activating factor and immunoglobulin G correlate with disease activity in systemic lupus erythematosus.
    Friebus-Kardash J; Branco L; Ribi C; Chizzolini C; Huynh-Do U; Dubler D; Roux-Lombard P; Dolff S; Kribben A; Eisenberger U; Trendelenburg M
    Nephrol Dial Transplant; 2018 Jan; 33(1):54-64. PubMed ID: 28992184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time.
    Becker-Merok A; Nikolaisen C; Nossent HC
    Lupus; 2006; 15(9):570-6. PubMed ID: 17080911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenotypic changes of lymphocytes in patients with systemic lupus erythematosus who are in longterm remission after B cell depletion therapy with rituximab.
    Iwata S; Saito K; Tokunaga M; Yamaoka K; Nawata M; Yukawa S; Hanami K; Fukuyo S; Miyagawa I; Kubo S; Tanaka Y
    J Rheumatol; 2011 Apr; 38(4):633-41. PubMed ID: 21159836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.